» Articles » PMID: 25605243

Targeting MiR-381-NEFL Axis Sensitizes Glioblastoma Cells to Temozolomide by Regulating Stemness Factors and Multidrug Resistance Factors

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Jan 22
PMID 25605243
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA-381 (miR-381) is a highly expressed onco-miRNA that is involved in malignant progression and has been suggested to be a good target for glioblastoma multiforme (GBM) therapy. In this study, we employed two-dimensional fluorescence differential gel electrophoresis (2-D DIGE) and MALDI-TOF/TOF-MS/MS to identify 27 differentially expressed proteins, including the significantly upregulated neurofilament light polypeptide (NEFL), in glioblastoma cells in which miR-381 expression was inhibited. We identified NEFL as a novel target molecule of miR-381 and a tumor suppressor gene. In human astrocytoma clinical specimens, NEFL was downregulated with increased levels of miR-381 expression. Either suppressing miR-381 or enforcing NEFL expression dramatically sensitized glioblastoma cells to temozolomide (TMZ), a promising chemotherapeutic agent for treating GBMs. The mechanism by which these cells were sensitized to TMZ was investigated by inhibiting various multidrug resistance factors (ABCG2, ABCC3, and ABCC5) and stemness factors (ALDH1, CD44, CKIT, KLF4, Nanog, Nestin, and SOX2). Our results further demonstrated that miR-381 overexpression reversed the viability of U251 cells exhibiting NEFL-mediated TMZ sensitivity. In addition, NEFL-siRNA also reversed the proliferation rate of U251 cells exhibiting locked nucleic acid (LNA)-anti-miR-381-mediated TMZ sensitivity. Overall, the miR-381-NEFL axis is important for TMZ resistance in GBM and may potentially serve as a novel therapeutic target for glioma.

Citing Articles

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma.

Wu H, Gao W, Chen P, Wei Y, Zhao H, Wang F Heliyon. 2024; 10(21):e39984.

PMID: 39568843 PMC: 11577240. DOI: 10.1016/j.heliyon.2024.e39984.


Role of Non-coding RNAs in the Response of Glioblastoma to Temozolomide.

Goleij P, Pourali G, Raisi A, Ravaei F, Golestan S, Abed A Mol Neurobiol. 2024; 62(2):1726-1755.

PMID: 39023794 DOI: 10.1007/s12035-024-04316-z.


Unraveling the noncoding RNA landscape in glioblastoma: from pathogenesis to precision therapeutics.

Sandhanam K, Tamilanban T Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9475-9502.

PMID: 39007929 DOI: 10.1007/s00210-024-03265-7.


18β-glycyrrhetinic acid promotes gastric cancer cell autophagy and inhibits proliferation by regulating miR-328-3p/signal transducer and activator of transcription 3.

Yang Y, Nan Y, Du Y, Huang S, Lu D, Zhang J World J Gastroenterol. 2023; 29(27):4317-4333.

PMID: 37545635 PMC: 10401664. DOI: 10.3748/wjg.v29.i27.4317.


MDK induces temozolomide resistance in glioblastoma by promoting cancer stem-like properties.

Yu X, Zhou Z, Tang S, Zhang K, Peng X, Zhou P Am J Cancer Res. 2022; 12(10):4825-4839.

PMID: 36381313 PMC: 9641408.


References
1.
Meola J, Hidalgo G, Silva J, Silva L, Paz C, Ferriani R . Caldesmon: new insights for diagnosing endometriosis. Biol Reprod. 2013; 88(5):122. DOI: 10.1095/biolreprod.112.103598. View

2.
Wang J, Sakariassen P, Tsinkalovsky O, Immervoll H, Boe S, Svendsen A . CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2007; 122(4):761-8. DOI: 10.1002/ijc.23130. View

3.
Lwin Z, MacFadden D, Al-Zahrani A, Atenafu E, Miller B, Sahgal A . Glioblastoma management in the temozolomide era: have we improved outcome?. J Neurooncol. 2013; 115(2):303-10. DOI: 10.1007/s11060-013-1230-3. View

4.
Irollo E, Pirozzi G . CD133: to be or not to be, is this the real question?. Am J Transl Res. 2013; 5(6):563-81. PMC: 3786264. View

5.
He Q, Luo X, Zhou Q, Wang K, Li S, Li Y . Expression of nestin in ovarian serous cancer and its clinicopathologic significance. Eur Rev Med Pharmacol Sci. 2013; 17(21):2896-901. View